REG - AOTI, Inc. - Employee Share Purchase Plan

AotiAnnouncement

Yesterday 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA6582Ca&default-theme=true

RNS Number : 6582C  AOTI, Inc.  01 May 2026

1 May 2026

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Employee Share Purchase Plan

 

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering
outcomes-based care at home, by more durable healing of wounds and the
prevention of amputations, announces the establishment of an Employee Share
Purchase Plan (ESPP). CSC Global(1) is acting as administrator of and trustee
to, the ESPP.

 

The principal terms of the plan are as follows:

i.    Eligible employees elect to contribute for twelve months up to a
maximum monthly value of either GBP 300, USD 400 or EUR 350, which is
deducted from after tax pay and used to purchase Investment Shares.

ii.    Existing common shares ("Investment Shares") are acquired by the
trustee quarterly at the prevailing market price on behalf of participating
employees.

iii.   One new common share ("Matching Share") will be awarded to employees
at nil cost for every four Investment Shares purchased.

iv.   There is a three-year vesting period from the commencement of the ESPP
to qualify for Matching Shares.

v.    Matching Shares will be forfeited under certain conditions such as if
an employee leaves AOTI or sells the Investment Shares before the end of the
vesting period.

 

On 30 April 2026, the following PDMRs of the Company enrolled in the ESPP and
have committed to monthly contributions for twelve months as per the table
below:

 

 PDMR              Role                     Monthly Contribution
 Mike Griffiths    Chief Executive Officer  USD400
 Jayesh Pankhania  Chief Financial Officer  GBP300
 Anthony Moffatt   Chief Operating Officer  EUR350

 

(1)CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited
and CSC Employee Benefit Services (Jersey) Limited

 

 For more information:

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer         +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer           ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Joint Broker)

 Dr. Christopher Golden, James Steel                 +44 (0)20 7418 8900

 Panmure Liberum Limited (Joint Broker)              +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 FTI Consulting (Financial PR & IR)                  +44 (0)20 3727 1000

 Ben Atwell, Simon Conway,                           AOTI@fitconsulting.com (mailto:AOTI@fitconsulting.com)

 Natalie Garland-Collins

 

 

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. TWO(2)(®) therapy has
also recently received positive coverage recommendations from the Federal
Joint Committee (G-BA) in Germany and National Institute for Health and Care
Excellence (NICE) in the United Kingdom. Also see www.aotinc.net
(http://www.aotinc.net)

 

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCWPUWACUPQGCU



            Copyright 2019 Regulatory News Service, all rights reserved